CN112426428A - Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer - Google Patents
Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer Download PDFInfo
- Publication number
- CN112426428A CN112426428A CN201910787401.9A CN201910787401A CN112426428A CN 112426428 A CN112426428 A CN 112426428A CN 201910787401 A CN201910787401 A CN 201910787401A CN 112426428 A CN112426428 A CN 112426428A
- Authority
- CN
- China
- Prior art keywords
- raloxifene
- gastric cancer
- oxaliplatin
- medicine
- treating gastric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the field of medicines, and particularly relates to application of raloxifene and oxaliplatin combined medicine in preparation of a medicine for treating gastric cancer. The invention provides the application of the raloxifene and oxaliplatin combined drug in preparing the drug for treating gastric cancer for the first time, the raloxifene and oxaliplatin have obvious synergistic effect, the curative effect is effectively improved, the curative effect is more obvious compared with that of a single component, and the killing property to tumor cells is improved; effectively reduces the dosage, thereby reducing the toxic and side effects. The combined use of the two can also save the cost, reduce the economic burden of patients, provide a new way for preventing and treating gastric cancer, and have wide application prospect in the field of medicine and pharmacology.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of raloxifene and oxaliplatin combined medicine in preparation of a medicine for treating gastric cancer.
Background
Gastric cancer is a common malignant tumor of the digestive tract, ranks third in the cancer-related deaths worldwide, and is one of the main health burdens of society. In China, gastric cancer is the second most prevalent cancer and the second leading cause of cancer death, so the development of anti-gastric cancer drugs is the hot spot of anti-tumor research and development in China. At present, the main treatment means of the gastric cancer is chemotherapy, but the single chemotherapy curative effect of the gastric cancer is poor, and the median survival time is only 8-13 months.
Oxaliplatin is a third generation platinum anticancer drug following cisplatin and carboplatin, has the characteristics of good anticancer effect, wide adaptation diseases and the like, shows broad-spectrum in-vitro cytotoxicity and in-vivo antitumor activity in various tumor model systems including human gastric cancer models, and plays an important role in the clinical treatment of gastric cancer. However, most of oxaliplatin is prone to cause severe gastrointestinal reactions, nephrotoxicity, ototoxicity, neurotoxicity and bone marrow toxicity during clinical use. Meanwhile, oxaliplatin is easy to cause acquired drug resistance, so that the actual curative effect of oxaliplatin is seriously reduced, and the clinical use of the oxaliplatin is further limited.
Raloxifene is a selective estrogen receptor modulator, has selective agonistic or antagonistic activity on tissues acted by estrogen, is mainly used for preventing and treating osteoporosis of postmenopausal women, and can remarkably reduce the incidence rate of vertebral body fracture. Reports on the effect of raloxifene in combination with oxaliplatin have not yet been made. The invention researches the effect of raloxifene in sensitizing oxaliplatin for treating gastric cancer in a human gastric cancer model.
Disclosure of Invention
Object of the Invention
The application of raloxifene sensitization oxaliplatin in the preparation of the medicine for treating gastric cancer is provided, the curative effect of the compound is enhanced, and a basis is provided for the new application of old medicines.
Technical scheme
The invention provides application of raloxifene and oxaliplatin combined medicine in preparation of a medicine for treating gastric cancer.
Therefore, the application of the combination of raloxifene and oxaliplatin in preparing the anti-gastric cancer medicament and the anti-gastric cancer medicament containing both raloxifene and oxaliplatin are all within the protection scope of the invention.
Preferably, the gastric cancer is human gastric cancer cell AGS or MGC 803.
Preferably, the gastric cancer is a human gastric cancer tissue organoid.
In addition, preferably, the dosage ratio of the raloxifene to the oxaliplatin is 0.5-128 ng/ml: 8 μ g/ml.
Preferably, the dosage ratio of raloxifene to oxaliplatin is 0.5-128 ng/ml: 16. mu.g/ml.
Preferably, the dosage ratio of raloxifene to oxaliplatin is 0.5-128 ng/ml: 32. mu.g/ml.
Particularly preferably, the dosage ratio of raloxifene to oxaliplatin is 32 ng/ml: 16. mu.g/ml.
Advantageous effects
The invention discloses the discovery of raloxifene on the aspect of improving the sensitivity of gastric cancer cells to oxaliplatin for the first time, can realize the synergistic effect, realize the obvious improvement of the anti-tumor effect, and reduce the dosage of oxaliplatin through combined medication so as to reduce the toxic and side effects, thereby having obvious significance for the application of raloxifene and oxaliplatin combined medication to the anti-gastric cancer.
Drawings
FIG. 1 is a graph showing the results of the inhibition analysis of Raloxifene alone in gastric cancer cells by MTT assay.
FIG. 2 is a graph showing the results of MTT method for detecting the inhibition rate of oxaliplatin alone or in combination with raloxifene and oxaliplatin for gastric cancer cell treatment; wherein, A: analyzing the result of cell AGS; b: cell MGC803 results analysis.
FIG. 3 is a graph showing the results of the inhibition rate analysis of oxaliplatin alone or in combination with raloxifene and oxaliplatin for human gastric cancer tissue organoids.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
The kit materials used in the following examples are all commercially available unless otherwise specified.
Example 1 MTT assay to determine the sensitivity of different gastric cancer cells to Raloxifene
1. Experimental Material
(1) Medicine preparation: raloxifene hydrochloride is commonly used clinically, and the Raloxifene hydrochloride is used as a test medicament in the embodiment.
The chemical structural formula of the raloxifene hydrochloride is shown as follows:
(2) gastric cancer cell: human gastric cancer cells AGS and MGC 803.
(3) Commercial MTT kit.
2. Experiment grouping
(1) Control group: blank control, i.e. gastric cancer cells, were not treated with any drug.
(2) Experimental groups: gastric cancer cells were treated with different concentrations of raloxifene hydrochloride.
3. MTT method for detecting sensitivity of different tumor cells to raloxifene
(1) Human gastric cancer cells AGS and MGC803 are inoculated to a 96-well plate according to the number of 5000-9000 cells per well, and after the cells adhere to the wall, PBS solutions of raloxifene hydrochloride with different concentrations are respectively added. After 24 hours of incubation, 10. mu.l of 5mg/ml MTT was added to each well for another 4 hours, and then 100. mu.l of DMSO was added to each well after discarding the culture solution, and the absorbance of each well was read at 490nm using a microplate reader. Statistical analysis was performed on the data.
(2) The analysis result is shown in fig. 1, which indicates that raloxifene hydrochloride has a certain effect of inhibiting proliferation of gastric cancer cells, but the inhibition effect is weak.
Example 2 Effect of oxaliplatin alone or in combination with Raloxifene and oxaliplatin on gastric cancer cell inhibition Rate
1. Experimental Material
(1) Medicine preparation: raloxifene hydrochloride and oxaliplatin.
(2) Gastric cancer cell: human gastric cancer cells AGS and MGC 803.
(3) Commercial MTT kit.
2. Experiment grouping
(1) Control group: gastric cancer cells were treated with oxaliplatin only.
(2) Experimental groups: various concentrations of raloxifene hydrochloride and oxaliplatin are used in combination to treat gastric cancer cells.
3. MTT method for detecting sensitivity of gastric cancer cells to raloxifene and oxaliplatin combined drug
(1) Human gastric cancer cells AGS and MGC803 are inoculated to a 96-well plate according to the number of 5000-9000 cells per hole, and PBS solutions with different proportions of raloxifene hydrochloride and oxaliplatin are respectively added after the cells adhere to the wall. After 24 hours of incubation, 10. mu.l of 5mg/ml MTT was added to each well for another 4 hours, and then 100. mu.l of DMSO was added to each well after discarding the culture solution, and the absorbance of each well was read at 490nm using a microplate reader. Statistical analysis was performed on the data.
(2) The analysis result is shown in fig. 2, the addition of raloxifene on the basis of oxaliplatin can more obviously inhibit the proliferation of gastric cancer cells compared with the single drug, and the combined use of raloxifene and oxaliplatin shows that the treatment effect of gastric cancer is obviously improved and the synergistic treatment effect is realized.
Example 3 Effect of oxaliplatin alone or in combination with Raloxifene and oxaliplatin on human gastric carcinoma tissue organoid inhibition
1. Experimental Material
(1) Medicine preparation: raloxifene hydrochloride and oxaliplatin.
(2) Gastric cancer cell: human gastric cancer tissue organoids.
(3) The commercially available CellTiter-Glo 3D kit.
2. Experiment grouping
(1) Control group: treatment with oxaliplatin alone.
(2) Experimental groups: raloxifene hydrochloride and oxaliplatin at different concentrations are used in combination to treat human gastric cancer tissue organoids.
3. Sensitivity of human gastric cancer tissue organoids to combined administration of raloxifene and oxaliplatin
(1) Mixing the treated human gastric cancer cells with Matrigel, adding 50 mul of the mixed Mtrigel Matrigel into each well of a 48-well plate, adding 250 mul of complete culture medium into each well after gelling, and culturing in a cell culture box at 37 ℃ and with the concentration of CO2 being 5%. The culture solution is replaced every 3-4 days, and can be subcultured and frozen every 1-2 weeks. After the organoid modeling is successful, subculturing is carried out for drug treatment, culture solution containing different proportions of raloxifene hydrochloride and oxaliplatin is added into each hole, and the mixture is placed in an incubator for 5 days. Adding CellTiter-Glo 3D detection reagent with the same volume as the culture medium into each hole, shaking and uniformly mixing, incubating at room temperature for 25 minutes, detecting by using an enzyme-linked immunosorbent assay (ELISA) instrument, and performing statistical analysis on data.
(2) The analysis result is shown in figure 2, the addition of raloxifene on the basis of oxaliplatin can more obviously inhibit the cell proliferation of human gastric cancer tissue organoids compared with single drug, and the combined use of raloxifene and oxaliplatin shows that the treatment effect of gastric cancer is obviously improved and the synergistic treatment effect is realized.
Claims (7)
1. Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer.
2. Use according to claim 1, characterized in that: the dosage ratio of raloxifene to oxaliplatin is 0.5-128 ng/ml: 8 μ g/ml.
3. Use according to claim 1, characterized in that: the dosage ratio of raloxifene to oxaliplatin is 0.5-128 ng/ml: 16. mu.g/ml.
4. Use according to claim 1, characterized in that: the dosage ratio of raloxifene to oxaliplatin is 0.5-128 ng/ml: 32. mu.g/ml.
5. Use according to claim 1, characterized in that: the dosage ratio of raloxifene to oxaliplatin is 32 ng/ml: 16. mu.g/ml.
6. A preparation for treating gastric cancer is characterized in that: the composition consists of the composition as claimed in claims 1 to 5 and pharmaceutically acceptable auxiliary materials.
7. The formulation of claim 6, wherein: the preparation is in the form of injection, tablet, granule or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910787401.9A CN112426428A (en) | 2019-08-24 | 2019-08-24 | Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910787401.9A CN112426428A (en) | 2019-08-24 | 2019-08-24 | Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112426428A true CN112426428A (en) | 2021-03-02 |
Family
ID=74689629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910787401.9A Withdrawn CN112426428A (en) | 2019-08-24 | 2019-08-24 | Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112426428A (en) |
-
2019
- 2019-08-24 CN CN201910787401.9A patent/CN112426428A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102065865B (en) | Multiple myeloma treatments | |
| CN109310685A (en) | The combination treatment of NOTCH and PI3K/MTOR inhibitor for treating cancer | |
| CN111956804B (en) | Novel use of inhibitors of OTUB1 | |
| CN101429201A (en) | Lemon acid berbamine salt, preparation method and application thereof | |
| CN102688493B (en) | Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof | |
| CN102688489B (en) | Pharmaceutical composition containing triptolide, triptolide derivative and Bc1-2 inhibitor and application thereof | |
| CN112426428A (en) | Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer | |
| CN101229175A (en) | Medical applications of couple protopanoxadiol derivatives and compound body thereof | |
| CN109528731B (en) | Pharmaceutical composition with synergistic effect for treating multiple myeloma and application thereof | |
| CN113786491B (en) | An anti-tumor combined preparation containing tetrandrine, dihydroquercetin or quercetin | |
| CN112089710B (en) | Application of 4-hydroxyisoleucine in preparation of antitumor drugs | |
| CN111494385B (en) | Medicine for treating ovarian cancer and preparation method and application thereof | |
| CN111821303B (en) | Application of vortioxetine and salts thereof in preparation of antitumor drugs | |
| CN112438980A (en) | Application of mirtazapine and methotrexate combined medicine in preparation of liver cancer treatment medicine | |
| WO2021023291A1 (en) | Use of proflavine in treatment of lung cancers | |
| CN115212216A (en) | Pharmaceutical composition for resisting esophageal squamous carcinoma | |
| KR20140035974A (en) | Combined pharmaceutical compositions for the treatment of tumours | |
| CN101653607B (en) | Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and mitogen extracellular kinase inhibitor and application thereof | |
| CN102688490B (en) | Pharmaceutical composition containing evodiamine, evodiamine derivative and Bc1-2 inhibitor, and the application | |
| CN112438986A (en) | Application of losartan potassium and dacarbazine combined medicine in preparation of medicine for treating intestinal cancer | |
| CN101653606B (en) | Pharmaceutical composition containing protein kinase B inhibitor and epidermal growth factor recipient tyrosine kinase inhibitor and application thereof | |
| CN112843028A (en) | Application of vitamin K1 and temozolomide combined medicine in preparation of medicine for treating bile duct cancer | |
| CN109010354A (en) | Composition containing Imatinib and plant polyose | |
| CN109248171A (en) | Composition containing Imatinib and plant polyose | |
| CN112472704A (en) | Application of meloxicam and raltitrexed combined medicine in preparing medicine for treating lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210302 |
|
| WW01 | Invention patent application withdrawn after publication |